Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.
Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Zaanan A, et al. Among authors: goldberg rm. JCO Precis Oncol. 2020 Feb 26;4:PO.19.00237. doi: 10.1200/PO.19.00237. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923882 Free PMC article.
Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.
Goldberg RM, Hatfield AK, Kahn M, Sargent DJ, Knost JA, O'Connell MJ, Krook JE, Maillard JA, Wiesenfeld M, Schaefer PL, Tirona MT, Moertel CG. Goldberg RM, et al. J Clin Oncol. 1997 Nov;15(11):3320-9. doi: 10.1200/JCO.1997.15.11.3320. J Clin Oncol. 1997. PMID: 9363861 Clinical Trial.
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers.
Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O'Connell MJ, Witzig TE, Farr GH Jr, Goldberg RM, Thibodeau SN. Halling KC, et al. Among authors: goldberg rm. J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303. doi: 10.1093/jnci/91.15.1295. J Natl Cancer Inst. 1999. PMID: 10433618
Rapid reporting and review of an increased incidence of a known adverse event.
Sargent DJ, Goldberg RM, Mahoney MR, Hillman DW, McKeough T, Hamilton SF, Darcy JM, Anderson VL, Krook JE, O'Connell MJ. Sargent DJ, et al. Among authors: goldberg rm. J Natl Cancer Inst. 2000 Jun 21;92(12):1011-3. doi: 10.1093/jnci/92.12.1011. J Natl Cancer Inst. 2000. PMID: 10861314 No abstract available.
A three-outcome design for phase II clinical trials.
Sargent DJ, Chan V, Goldberg RM. Sargent DJ, et al. Among authors: goldberg rm. Control Clin Trials. 2001 Apr;22(2):117-25. doi: 10.1016/s0197-2456(00)00115-x. Control Clin Trials. 2001. PMID: 11306150
Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.
Erlichman C, Adjei AA, Alberts SR, Sloan JA, Goldberg RM, Pitot HC, Rubin J, Atherton PJ, Klee GG, Humphrey R. Erlichman C, et al. Among authors: goldberg rm. Ann Oncol. 2001 Mar;12(3):389-95. doi: 10.1023/a:1011183905848. Ann Oncol. 2001. PMID: 11332153 Free article. Clinical Trial.
433 results